In this study, we further demonstrated that the VEGFR3 inhibitor MAZ51 disrupted EphrinB2-enhanced lymphangiogenesis, thus abolishing the cardioprotective effects of EphrinB2 on post-MI phenotypes. The gene discussed is EFNB2; the disease is myocardial infarction.